Venous Thromboembolism Prophylaxis
|
|
- Wilfrid Dennis
- 5 years ago
- Views:
Transcription
1 Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January 6, 2015 Next Review (3 years from Effective Date) January 2018 Purpose Policy Statement Applicability To minimize the risk of venous thromboembolism to patients admitted to Covenant Health acute care facilities by requiring assessment for risk of venous thromboembolism. Patients admitted to Covenant Health acute care facilities shall be assessed for their risk of venous thromboembolism and receive optimal evidence based thromboprophylaxis. This policy and procedure applies in all Covenant Health acute care facilities, and all staff, members of the medical staff, volunteers, students and any other persons acting on behalf of Covenant Health. Responsibility The most responsible health practitioner is responsible to complete an assessment of risk of venous thromboembolism (VTE) and bleeding risk. During the course of treatment, all health care professionals shall demonstrate compliance with this policy on an ongoing basis by identifying patients who are at risk that are not receiving thromboprophylaxis or whose bleeding risk has subsided. This information is to be provided to the patient s health care team immediately. Principles Policy Elements Venous thromboembolism is one of the most common complications of hospitalization and the most common preventable cause of hospital death. 1. Assessment for Venous Thromboembolism Risk 1.1 Every adult (18 years of age and older) acute care hospitalized patient shall be assessed for venous thromboembolism risk at the time of admission to hospital, at the time of a significant change in clinical status, at the time of transfer from one type of care to another, and at discharge. 2. Commencement of Venous Thromboprophylaxis 2.1 Optimal, evidence-based thromboprophylaxis shall be provided to every adult acute care patient in whom it is indicated based on their risk of thrombosis, their risk of bleeding, and available options in the facility. Procedure Definitions Covenant Health health care professionals shall adhere to the Covenant Health Practice Support Document Guidelines for Venous Thromboembolism Prophylaxis (as adapted from Alberta Health Services). Deep vein thrombosis means a thrombus (blood clot) occurring in one or more deeper veins, especially in the legs, where it may produce leg swelling and/or pain. Health care professional means an individual who is a member of a regulated health discipline, as defined by the Health Disciplines Act or the Health Professions Act, and
2 2 of 12 who practices within scope or role. Most responsible health practitioner means the health practitioner who has responsibility and accountability for the specific treatment/procedure(s) provided to a patient and who is authorized by Covenant Health to perform the duties required to fulfill the delivery of such a treatment/procedure(s) within the scope of his/her practice. Patient means all persons who receive or have requested health care or services from Covenant Health and its health care providers. This term is inclusive of residents and clients Thromboprophylaxis means the use of mechanical methods or anticoagulant medication to prevent venous thromboembolism from developing in patients who are at risk. Venous thromboembolism (VTE) means a thromboembolic event (blood clot) that develops within the venous system and includes both deep vein thrombosis and pulmonary embolism. Related Documents Venous Thromboembolism Prophylaxis Practice Support Document Guideline (attached) References Alberta Health Services Venous Thromboembolism Prophylaxis Policy Level 1 Chronological Revision Date(s) N/A
3 3 of 12 PRACTICE SUPPORT DOCUMENT for VENOUS THROMBOEMBOLISM PROPHYLAXIS Objectives Applicability To outline the recommended approach to venous thromboembolism (VTE) prophylaxis for all adult patients admitted to a Covenant Health acute care facility. This policy and procedure applies in all Covenant Health acute care facilities, and all staff, members of the medical staff, volunteers, students and any other persons acting on behalf of Covenant Health. GUIDELINE: The underlying principle guiding the use of VTE is that all adult acute care patients at risk receive optimal evidence based venous thromboprophylaxis. An assessment of risk of VTE and bleeding risk should be made by the most responsible health practitioner at the time of admission to an acute care facility. All health care professionals should identify patients who are at risk that are not receiving thromboprophylaxis or whose bleeding risk has subsided. This information is to be provided to the patient s health care team immediately. The approach to thromboprophylaxis involves three steps: STEP 1 Is Thromboprophylaxis NOT INDICATED? 1.1 For patients who are at their normal levels of mobility and expected to have a length of stay less than 48 hours, thromboprophylaxis is generally not needed unless multiple other VTE risk factors are present. 1.2 If no specific thromboprophylaxis is provided, patients should be encouraged to be as mobile as possible. 1.3 If a patient s clinical status changes significantly, a decision about thromboprophylaxis should be reassessed at that time. 1.4 For patients who are identified as receiving end of life care, anticoagulant prophylaxis is not given. STEP 2 Is Anticoagulant Thromboprophylaxis CONTRAINDICATED? 2.1 Absolute contraindications to anticoagulant thromboprophylaxis are: a) active, clinically-important bleeding; b) platelets less than 50 x 10 9 /L and/or; c) major bleeding disorder.
4 4 of Relative contraindications to anticoagulant thromboprophylaxis are: a) recent intracranial haemorrhage; b) recent perispinal bleeding and/or; c) recent high-risk bleeding surgery. 2.3 For patients who are actively bleeding or have a high risk of bleeding (see Table 1, High Bleeding Risk Considerations in Hospitalized Medical Patients, for more details), anticoagulant prophylaxis is not given. In this situation, bilateral, properly measured and fitted, calf-length graduated compression stockings (GCSs) or sequential compression devices (SCP) are placed. a) These patients should be reassessed daily for proper use of the stockings/compression device and bleeding risk. When the high bleeding risk decreases, anticoagulants should be started. - Table 1 - High Bleeding Risk Considerations in Hospitalized Medical Patients *Peptic ulcer disease Hepatic failure Age (greater than 75 years of age) *Prior bleeding history Rheumatic diseases Renal failure *Thrombocytopenia Active cancer Intensive Care Unit / Coronary Care Unit stay Decousus et al, Chest 2011:69 * Indicates high bleeding risk either as a single factor or associated with other risk factors. 2.4 For patients with heparin-induced thrombocytopenia (HIT), either currently or in the past, unfractionated heparin (UFH) or low molecular weight heparin (LMWH) is contraindicated. In this setting, the internal medicine or haematology service should be contacted for advice the most appropriate thromboprophylaxis in the setting of HIT is generally fondaparinux 2.5 milligrams (mg) subcutaneously (sc) once daily or intravenous argatroban. a) In order to avoid the higher risk of HIT, use of UFH should be minimized.
5 5 of 12 STEP 3 Provide Thromboprophylaxis 3.1 Assess risk of VTE based on known risk factors: a) See Table 2, Risk Factors for VTE. - Table 2 - Risk Factors for VTE Age greater than 60 years Inflammatory Bowel Disease (IBD) Obesity Active cancer Estrogen therapy Immobility Intubation Pregnancy and post partum Surgery Thrombophilia Trauma Myeloproliferative disorders Prior VTE Nephrotic syndrome Severe acute respiratory illness or Congestive Heart Failure (CHF) b) See Table 3, Levels of Thromboembolism Risk and Recommended Thromboprophylaxis in Hospital Patients
6 6 of 12 - Table 3 - Levels of Thromboembolism Risk and Recommended Thromboprophylaxis in Hospital Patients Level of VTE Risk Low Moderate High Very High High bleeding risk Risk Factors for VTE Minor surgery Mobile medical patient Age less than 60 years Most general, gynecology or urological surgery patients Immobilized medical patients Age greater than 75 years Additional risk factors for VTE Hip or knee arthroplasty Major trauma Hip fracture Spinal cord injury Approximate Deep Vein Thrombosis (DVT) Risk Without Prophylaxis Less than 10% 10 40% 40 60% 40 80% Suggested Thromboprophylaxis Options Early Ambulation LMWH LDUH bid or tid Fondaparinux LMWH LDUH tid Fondaparinux LMWH Fondaparinux Vitamin K Antagonist AntiXa inhibitors Mechanical prophylaxis with IPDs Fondaparinux (suggest consult to Internal Medicine or Haematology Service) 3.2 For most patients, the recommended thromboprophylaxis is low molecular weight heparin (LMWH) once daily. a) In general, for weight less than 40 kg, it is recommended that a dose reduction be considered. b) In general, for weight greater than 100 kg, it is recommended that a dose increase be considered. For weight greater than 120 kg, even higher doses should be considered. c) A dosage reduction is recommended for prophylactic doses of LMWH for patients with severe renal impairment (creatinine clearance less than 30 ml/min.) For patients with creatinine clearance less than 20 ml/min, low dose unfractionated heparin prophylaxis is preferred over LMWH.
7 7 of 12 d) For arthroplasty patients, the first dose of LMWH is generally given six hours post operatively and then daily. e) If patients are already receiving LMWH and are scheduled for an epidural insertion, it is recommended that the anticoagulant is held for 18 to 24 hours prior to insertion. f) For patients with epidural catheters, the LMWH dose is held to facilitate catheter removal in the morning and to allow for at least 18 hours after the previous LMWH dose before catheter removal. For patients who have had an epidural catheter removed, the next dose of LMWH should be delayed for at least two hours after removal.
8 8 of 12 APPENDIX A General Considerations: RECOMMENDED THROMBOPROPHYLAXIS THERAPY BY PATIENT GROUP 1. Although the recommended options apply to most patients in each group, individual patient factors may suggest an alternate approach. 2. For all patients in whom it is possible and appropriate, early and frequent mobilization and ambulation are essential. 3. In general, for weight less than 40 kg or creatinine clearance less than 30 ml/minute, it is suggested that the prophylactic LMWH dose be reduced to the next lower pre-filled syringe dose for enoxaparin only. In general, for weight greater than 100 kg, consider doubling the LMWH dose. At weights greater than 120 kg, even higher doses should be considered. 4. The duration of Thromboprophylaxis is not based on mobility status alone. Given evidence suggest low to moderate bleeding risk associated with use of prophylactic dosages of LMWH, in absence of clinically significant bleeding or in setting of procedures involving critical areas where achieving hemostasis is limited or potentially catastrophic bleeding is possible, in most instances, TP should not be withheld. [Bump, 2008] Legend for following chart: ER = emergency room GCS = graduated compression stockings TP = thromboprophylaxis SCD = sequential compression devices UFH = unfractionated heparin LMWH = low molecular weight heparin TJR = total joint replacement VTE = venous thromboembolism LDUH = low dose unfractionated heparin
9 9 of 12 Patient Group High bleeding risk Neuraxial blockage / spinal anaesthesia Heparin-induced thrombocytopenia (HIT) current or previous Recommended Thromboprophylaxis Options Properly fitted bilateral calf-length GCS or SCD used continuously (except for bathing or ambulating). UFH bid / tid Can use LMWH after epidural removed If LMWH has been given, hold LMWH for 18 to 24 hours prior to insertion or removal of neuraxial catheter Suggest haematology / internal medicine consult No heparin or LMWH Fondaparinux 2.5 mg SC once daily or argatroban Initiation ASAP after emergency admission. Just prior to surgery for elective surgical procedures. 2-4 hours after insertion of neuraxial catheter At least two hours after removal of neuraxial catheter As soon as the diagnosis of HIT considered. Burn unit patients LMWH q 24 hours or LDUH bid / tid When there is evidence of primary hemostasis Duration Until bleeding risk allows the use of anticoagulants. Discharge and platelet count greater than 120 x 10 9 /L Cardiovascular surgery LMWH q 24 hours or LDUH bid / tid Primary hemostasis Unit discharge Chronic kidney disease UFH bid / tid On admission Critical care General Surgery (major) Use Critical Care order sets In most cases, the prophylaxis is LMWH q 24 hours or LDUH bid / tid properly fitted bilateral calf-length GCS or SCD until anticoagulants can be started Use General Surgery order sets In most cases, the prophylaxis is LMWH q 24 hours or LDUH bid / tid properly fitted bilateral calf-length GCS First dosing time after admission, if possible See Critical Care order sets 0-1 hour pre-op (if no epidural) or 2-4 hours after insertion of epidural Include TP in transfer orders
10 10 of 12 Patient Group Recommended Thromboprophylaxis Options or SCD until LMWH can be started Initiation Duration Gynecology Use Gynecology order sets In most cases, the prophylaxis is LMWH q 24 hours or LDUH bid / tid properly fitted bilateral calf-length CGS or SCD until anticoagulants can be started First dosing time after ER admission or post-op; or the following morning if there are bleeding concerns Hip and knee arthroplasty Use Arthroplasty order sets In most cases, the prophylaxis is LMWH q 24 hours For patients with moderate renal dysfunction, use dose reduced LMWH SC q 24 hours or LDUH bid Or fondaparinux or rivaroxaban or Vitamin K antagonist Six hours post-op 15 days 28 days if higher risk and THR Hip fracture Use Hip Fracture order sets LMWH q 24 hours or fondaparinux or warfarin Dosage reduction if weight less than 40 kg or CrCl less than 30 ml/min If surgery is delayed, start LMWH on admission days Internal medicine (and medical subspecialties) Use Medicine admission order sets / DVT prophylaxis order sets For most patients, LMWH q 24 hours; or LDUH bid / tid or fondaparinux Dosage adjustment for high or low weight and renal dysfunction properly fitted bilateral calf-length GCS/SCD until anticoagulant can be First dosing time after admission Consider extended for cancer, stroke
11 11 of 12 Patient Group Recommended Thromboprophylaxis Options Initiation Duration started Neurosurgery Three options: properly fitted bilateral calf-length GCS or SCD LMWH q 24 hours LDUH bid / tid Start with bilateral calf-length GCS/SCD and switch to LMWH when risk of bleeding decreases For GCS/SCD, start just prior to surgery for elective surgical procedures and ASAP after admission for major neurotrauma or non-traumatic intracranial hemorrhage For LMWH, no sooner than day after surgery Obstetrics LMWH q 24 hours Initial dose of UFH given immediately post caesarean for high risk individuals LMWH started at least 2 hours after epidural removed Extended for 6 weeks and/or converted to warfarin for those with prior VTE or with thrombophilia Oncology (medical and radiation) LMWH q 24 hours properly fitted bilateral calf-length GCS or SCD until LMWH can be started First dosing time after admission Consider benefits vs. risk of post-discharge TP Pediatrics Early mobilization except in very high risk population No clear evidence supporting TP in pediatric population Plastic Surgery LMWH q 24 hours, fondaparinux, LDUH bid / tid Pre-op or post-op 6-12 hours Spinal cord injury LMWH q 12 or 24 hours ASAP after admission (once hemostasis is evident) from rehab Spine surgery LMWH q 24 hours Evening or morning after surgery Stroke ischemic Use Stroke admission order sets First dosing time after admission
12 12 of 12 Patient Group Recommended Thromboprophylaxis Options For most patients, LMWH q 24 hours Dosage adjustment for low or high weight and renal dysfunction properly fitted bilateral calf-length GCS or SCD until LMWH can be started Initiation Duration Stroke hemorrhagic Use Stroke admission order sets Bilateral, properly fitted calf-length GCS or SCD After approx. 5-7 days, consider switch to LMWH as for ischemic stroke On admission Sub-Acute Care LMWH q 24 hours or LDUH bid For extended prophylaxis in spinal cord injury, stroke associated with paralysis, hip fracture or total joint and abdominal / pelvic cancer therapy Continuation of prophylaxis at transitions days Trauma properly fitted bilateral calf-length GCS/SCD until LMWH can be started Usual risk patients: LMWH q 24 hours High risk patients (lower extremity fracture): LMWH q 12 hours ASAP after admission (once hemostasis is evident) from rehab Urology Use Urology order sets In most cases the prophylaxis is LMWH q 24 hours or LDUH bid properly fitted bilateral calf-length GCS/SCD until LMWH can be started Options: First dosing time after surgery Morning after surgery if there are bleeding concerns First dosing time after ER admission or post-op
NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE VENOUS THROMBOEMBOLISM PROPHYLAXIS SCOPE Provincial Acute and Sub-Acute Care Facilities APPROVAL AUTHORITY Alberta Health Services Executive Committee SPONSOR Vice President, Quality and Chief Medical
More informationTHROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY
THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY OBJECTIVE: To outline a practical approach for the prevention of venous thromboembolism (VTE) in patients undergoing non-orthopedic surgery. BACKGROUND: VTE is
More informationINDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY
INDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY N.E. Pearce INTRODUCTION Preventable death Cause of morbidity and mortality Risk factors Pulmonary embolism
More information1. SCOPE of GUIDELINE:
Page 1 of 35 CLINICAL PRACTICE GUIDELINE: Venous Thromboembolism (VTE) Prevention Guideline: Thromboprophylaxis AUTHORIZATION: VP, Medicine Date Approved: May 17, 2012 Date Revised: Vancouver Coastal Health
More informationObjectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?
Objectives Venous Thromboembolism (VTE) Prophylaxis Rishi Garg, MD Department of Medicine Identify patients at risk for VTE Options for VTE prophylaxis Current Recommendations (based on The Seventh ACCP
More informationPerioperative VTE Prophylaxis
Perioperative VTE Prophylaxis Gregory J. Misky, M.D. Assistant Professor of Medicine University Of Colorado Denver You recommend the following 72 y.o. man admitted for an elective R hip repair. Patient
More informationVenous Thromboembolism. Prevention
Venous Thromboembolism Prevention August 2010 Venous Thromboembloism Prevention 1 1 Expected Practice Assess all patients upon admission to the ICU for risk factors of venous thromboembolism (VTE) and
More informationPrevention of Venous Thromboembolism
Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH President and CEO Dale W. Bratzler, DO, MPH Oklahoma Foundation for Medical Quality QIOSC Medical Director
More informationGetting Started Kit VENOUS THROMBOEMBOLISM PREVENTION. Section 2: Evidence-Based Appropriate VTE Prophylaxis
Reducing Harm Improving Healthcare Protecting Canadians VENOUS THROMBOEMBOLISM PREVENTION Getting Started Kit Section 2: Evidence-Based Appropriate VTE Prophylaxis January 2017 www.patientsafetyinstitute.ca
More informationMisunderstandings of Venous thromboembolism prophylaxis
Misunderstandings of Venous thromboembolism prophylaxis Veerendra Chadachan Senior Consultant Dept of General Medicine (Vascular Medicine and Hypertension) Tan Tock Seng Hospital, Singapore Case scenario
More informationAnticoagulation for prevention of venous thromboembolism
Anticoagulation for prevention of venous thromboembolism Original article by: Michael Tam Note: updated in June 2009 with the eighth edition (from the seventh) evidence-based clinical practice guidelines
More informationVenous Thromboembolism (VTE) Prevention
Venous Thromboembolism (VTE) Prevention 7 VTE Risk Assessment: General Patient Population Assess VTE risk at admission, post-op, and transfer See page 2 for VTE risk assessment among Obstetrical (OB) patients
More informationVenous Thromboembolism Prophylaxis: Checked!
Venous Thromboembolism Prophylaxis: Checked! William Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University of Toronto National Lead, VTE Prevention, Safer
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationSlide 1. Slide 2. Slide 3. Outline of This Presentation
Slide 1 Current Approaches to Venous Thromboembolism Prevention in Orthopedic Patients Hujefa Vora, MD Maria Fox, RN June 9, 2017 Slide 2 Slide 3 Outline of This Presentation Pathophysiology of venous
More informationNICE Guidance: Venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital 1
The College of Emergency Medicine Patron: HRH The Princess Royal Churchill House Tel +44 (0)207 404 1999 35 Red Lion Square Fax +44 (0)207 067 1267 London WC1R 4SG www.collemergencymed.ac.uk CLINICAL EFFECTIVENESS
More informationTHROMBOSIS RISK FACTOR ASSESSMENT
Name: Procedure: Doctor: Date: THROMBOSIS RISK FACTOR ASSESSMENT CHOOSE ALL THAT APPLY EACH RISK FACTOR REPRESENTS 1 POINT Age 41 60 years Minor Surgery Planned History of Prior Major Surgery (< 1 month)
More informationDVT - initial management NSCCG
Background information Information resources for patients and carers Updates to this care map Synonyms Below knee DVT and bleeding risks Patient with confirmed DVT Scan confirms superficial thrombophlebitis
More informationPrevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales
Prevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales Merimbula, 6 th November 2010 University of Sydney Department of Surgery Westmead Hospital
More informationThese are guidelines only and can be deviated from if it is thought to be in the patient s best interest.
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics Venous thromboembolism (VTE) is a recognised complication associated with inactivity and surgical procedures. Therefore, all
More information10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline
Disclosures Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines No relevant conflicts of interest related to the topic presented. Cyndy Brocklebank, PharmD, CDE Chronic Disease Management
More informationVenous thromboembolism - reducing the risk
Venous thromboembolism - reducing the risk Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital NICE guideline Draft for consultation,
More informationVenothromboembolism prophylaxis: Trauma and Orthopaedics Clinical guideline, V2
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics 11/11/11 TEMPORARY GUIDANCE There is no prophylactic tinzaparin available in the Trust currently. Please substitute enoxaparin
More informationReducing the risk of venous thrombo-embolism (VTE) in hospital and after discharge
Reducing the risk of venous thrombo-embolism (VTE) in hospital and after discharge What is a venous thromboembolism (VTE)? This is a medical term that describes a blood clot that develops in a deep vein
More informationVenous thromboembolism: reducing the risk
Issue date: January 2010 Venous thromboembolism: reducing the risk Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital This guideline
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationNoCVA Hospital Engagement Network SSI/VTE Safe Surgery Collaborative. December 13, 2012
NoCVA Hospital Engagement Network SSI/VTE Safe Surgery Collaborative December 13, 2012 1 Hospital Acquired VTE Preventing a Preventable Problem It takes a commitment from ALL members of the healthcare
More informationVENOUS THROMBOEMBOLISM (VTE) PREVENTION MEDICAL PROVIDER EDUCATION JUNE 2017
VENOUS THROMBOEMBOLISM (VTE) PREVENTION MEDICAL PROVIDER EDUCATION JUNE 2017 VTE IS THE 2 ND MOST COMMON HOSPITAL ACQUIRED CONDITION RISK FACTORS DECREASED ACTIVITY = VTE RISK (NURSES MEASURE WITH BRADEN
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationVTE Management in Surgical Patients: Optimizing Prophylaxis Strategies
VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies VTE in Surgical Patients: Recognizing the Patients at Risk Pathogenesis of thrombosis: Virchow s triad and VTE Risk Hypercoagulability
More informationADULT TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) TELEMETRY BED TRANSFER ORDERS 1 of 4
TELEMETRY BED TRANSFER 1 of 4 9 Actual 9 Estimated Patient ID Area Weight kg 9 Actual 9 Estimated Height cm ALLERGIES: REFER TO ALLERGY PROFILE/ POWERCHART Transfer to: 10 South Attending Physician: Diagnosis:
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationTarkten A Pharr, MD, FACS 04/26/2018. VTE Prevention Strategies: Is a One Size Fits all Approach Correct?
Tarkten A Pharr, MD, FACS 04/26/2018 VTE Prevention Strategies: Is a One Size Fits all Approach No disclosures... Why do we care? Where is this is the realm of public health concerns? Incidence/Prevalence
More informationDENOMINATOR: All surgical patients aged 18 years and older undergoing procedures for which VTE prophylaxis is indicated in all patients
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2017 OPTIONS FOR INDIVIDUAL MEASURES:
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationVenous Thromboembolism (VTE) Prevention and Treatment of VTE in Patients Admitted to Hospital
Please Note: This policy is currently under review and is still fit for purpose. Venous Thromboembolism (VTE) Prevention and Treatment of VTE in Patients Admitted to Hospital This procedural document supersedes
More informationAdmit date (YYYY/MM/DD): Cardiologist On-Call: Diagnosis: Lab Tests. CBC, Electrolytes, Urea, Creatinine, Glucose, INR, PTT, Urinalysis
of nurse 1. Admit under ward Attending Physician: Dr. Admit date (YYYY/MM/DD): Cardiologist On-Call: Diagnosis: Lab Tests 2. On admission (if not already performed in Emergency Department or in Coronary
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationProphylaxis for Hospitalized and Non-Hospitalized Medical Patients
Prophylaxis for Hospitalized and Non-Hospitalized Medical Patients An Educational Slide Set American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism Slide set authors: Eric
More informationHEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,
More informationEarly Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Marilyn Szekendi, PhD, RN
Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement Marilyn Szekendi, PhD, RN ANA 7 th Annual Nursing Quality Conference, February 2013 Research Team Banafsheh Sadeghi,
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationIF YOU RECEIVED THIS FACSIMILE IN ERROR, PLEASE CALL IMMEDIATELY. ADMISSION INSTRUCTIONS: Admitted to Dr.
ADMISSION INSTRUCTIONS: Admitted to Dr. Procedure: Right Hip Left Hip CODE STATUS: Full DNR level of intervention DIET: Dysphagia screen consult SLP High protein, high energy Regular Nutrient dense Boost
More informationOrthopedic Admission Hip Fracture Version 2 1/25/2017
Patient Name: Initial each page and Sign/Date/Time last page Diagnosis: Allergies with reaction type: Orthopedic Admission Hip Fracture Version 2 1/25/2017 Patient Placement Patient Status If the physician
More informationInhixa (Enoxaparin Sodium)
Inhixa (Enoxaparin Sodium) P R E V ENTIS SAFETY D E V I C E P R E V E N T I S I S A N AU TO M AT I C N E E D L E S H I E L D I N G S Y S T E M, W H I C H H A S A C O V E R T H AT E X T E N D S O V E R
More informationVenous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital
Venous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital VTE is common and dangerous 5 VTE is Common VTE Incidence: 1.5 / 1000 per year
More informationVenous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community
Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationADULT CARDIAC SURGERY TELEMETRY BED TRANSFER ORDERS 1 of 4
ADULT CARDIAC SURGERY TELEMETRY BED TRANSFER 1 of 4 9 Actual 9 Estimated Attending Surgeon: Medical Record Number Weight kg 9 Actual 9 Estimated Height cm ALLERGIES: REFER TO ALLERGY PROFILE/ POWERCHART
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationCPT only copyright 2014 American Medical Association. All rights reserved. 12/23/2014 Page 66 of 593
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2015 PQRS OPTIONS FOR INDIVIDUAL MEASURES:
More informationGENERAL SURGICAL ADULT POST-OPERATIVE ORDERS 1 of 4
down ADULT POST-OPERATIVE 1 of 4 9 Actual 9 Estimated Patient ID Area Weight kg 9 Actual 9 Estimated Height cm ALLERGIES: REFER TO ALLERGY PROFILE/ POWERCHART Admit to: Post Anesthesia Care Unit (PACU),
More informationOBSTETRIC ADMISSION ORDERS 1 of 4
OBSTETRIC ADMISSION 1 of 4 Actual Estimated Weight kg Actual Estimated Height cm ALLERGIES: REFER TO ALLERGY PROFILE/ POWERCHART ADMIT TO: Labor and Delivery ( ) Check, circle and/or fill in all orders
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationGuideline Quick View: Venous Thromboembolism
Guideline Quick View: Venous Thromboembolism The AORN Guideline Quick View is a key component of Guideline Essentials, a suite of online implementation tools designed to help the perioperative team translate
More informationLow Risk Non-surgical medicine patients without any Mechanical prophylaxis
ADULT VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS GUIDELINE This document is intended as a guideline only and should not replace sound clinical judgment. I. VTE risk assessment and selection of prophylaxis:
More informationWhat You Should Know
1 New 2018 ASH Clinical Practice Guidelines on Venous Thromboembolism: What You Should Know New 2018 ASH Clinical Practice Guidelines on Venous Thromboembolism: What You Should Know The American Society
More information*Corresponding Author:
Audit of venous thromboembolism prophylaxis administered to general surgical patients undergoing elective and emergency operations at National Hospital, Sri Lanka *Migara Seneviratne 1, Asanka Hemachandra
More informationDr. Steve Ligertwood Dr. Roderick Tukker Dr. David Wilton
Dr. Steve Ligertwood Hospitalist Royal Columbian Hospital Regional Department Head-Hospitalist for Fraser Health Authority Project Lead BC Hospitalist VTE Collaborative Clinical Instructor, UBC School
More informationThromboprophylaxis in Adult General Medical Patients - Guidelines for Management
Thromboprophylaxis in Adult General Medical Patients - Guidelines for Management Adapted from the Worcestershire Acute Hospitals NHS Trust Guideline WAHT-MED-010 Version: Final Ratified by: Provider Quality
More informationGeneral. Recommendations. Guideline Title. Bibliographic Source(s) Guideline Status. Major Recommendations
General Guideline Title Prevention of deep vein thrombosis and pulmonary embolism. Bibliographic Source(s) American College of Obstetricians and Gynecologists (ACOG). Prevention of deep vein thrombosis
More informationFactor Xa Inhibition in the Management of Venous Thromboembolism: Important Safety Information. Important Safety Information (cont d)
Factor Xa Inhibition in the Management of Venous Thromboembolism: The Role of Fondaparinux WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with
More informationCoversheet for Network Site Specific Group Agreed Documentation
Coversheet for Network Site Specific Group Agreed Documentation This sheet is to accompany all documentation agreed by Pan Birmingham Cancer Network Site Specific Groups. This will assist the Network Governance
More informationShared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Version 5.2 Version: 5.2 Authorised by: Joint Medicines
More informationLow Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders
SURGICAL GRAND ROUNDS March 17 th, 2007 Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders Guillermo Escobar, M.D. LMWH vs UFH Jayer s sales pitch: FALSE LMW is
More informationRisk factors for DVT. Venous thrombosis & pulmonary embolism. Anticoagulation (cont d) Diagnosis 1/5/2018. Ahmed Mahmoud, MD
Risk factors for DVT Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior
More informationVenous thrombosis & pulmonary embolism. Ahmed Mahmoud, MD
Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Risk factors for DVT Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior
More informationNew v1.0 Date: December 2015 Patricia Wain - Associate Director Physical Care. Kenny Laing - Deputy Director of Nursing
Clinical Venous Thromboembolism: Standing Operating Procedure Document Control Summary Status: Version: Author/Title: Owner/Title: New v1.0 Date: December 2015 Patricia Wain - Associate Director Physical
More informationVTE Prevention Guidelines (Venous Thromboembolism) (Venous Thromboembolism)
VTE Prevention Guidelines (Venous Thromboembolism) (Venous Thromboembolism) When using this document please ensure that the version you are using is the most up to date either by checking on the Trust
More informationMeasure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) 2013 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage
More informationWMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT
WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT - Entering orders for anticoagulation in Cerner Providers will enter individual orders (oneoffs)
More informationTRANSPARENCY COMMITTEE OPINION. 18 April 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 April 2007 ARIXTRA 2.5 mg/0.5 ml, solution for injection in prefilled syringe Pack of 2 (CIP: 359 225-4) Pack of
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationDisclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None
Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)
More informationVTE in the Trauma Population
VTE in the Trauma Population Erik Peltz, D.O. February 11 th, 2015 * contributions from Eduardo Gonzalez, M.D. University of Colorado T-32 Research Fellow The problem. VTE - Scope of the Problem One of
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationDeep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H
Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H Authors' objectives To systematically review the incidence of deep vein
More informationAppendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS
Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS Please note that newer oral anticoagulants e.g. rivaroxaban, dabigatran and apixiban should be only be considered in patients with
More informationGuidelines for Prevention of Venous Thromboembolism in Adults
Guidelines for Prevention of Venous Thromboembolism in Adults First Edition (2011) www.savte.com Dear Colleagues, It is our pleasure to introduce this booklet of guidelines for venous thromboembolism (VTE)
More informationAre guidelines for anticoagulation useful in cancer patients?
Session 3 Striking a Balance Between Bleeding and the Risk of Thrombosis in Cancer Patients Are guidelines for anticoagulation useful in cancer patients? Sebastian Szmit Department of Pulmonary Circulation
More informationDeep Vein Thrombosis
Deep Vein Thrombosis from NHS (UK) guidelines Introduction Deep vein thrombosis (DVT) is a blood clot in one of the deep veins in the body. Blood clots that develop in a vein are also known as venous thrombosis.
More informationARTEMIS. ARixtra (fondaparinux) for ThromboEmbolism prevention in. a Medical Indications Study. NV Organon Protocol 63129
ARTEMIS ARixtra (fondaparinux) for ThromboEmbolism prevention in NV Organon Protocol 63129 a Medical Indications Study Objective To demonstrate efficacy and to assess safety of oncedaily subcutaneous (SC)
More informationWARFARIN: PERI-OPERATIVE MANAGEMENT
WARFARIN: PERI-OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin-treated patients who require an elective or urgent surgery/procedure. To provide an approach
More informationWARFARIN: PERI OPERATIVE MANAGEMENT
WARFARIN: PERI OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin treated patients who require an elective or urgent surgery/procedure. To provide an approach
More informationJessica Bryan, Natalia Evans, Karlyn Henderson, & Whitney Parks
Jessica Bryan, Natalia Evans, Karlyn Henderson, & Whitney Parks 1. What is the most common cause of death in hospitalized patients? 1. Hospital-acquired infection 2. Pulmonary embolism 3. Myocardial infarction
More informationGUIDELINE FOR THROMBOPROPHYLAXIS IN ADULT (18 YEARS AND OLDER) IN GENERAL MEDICAL PATIENTS AND INPATIENTS UNDERGOING SURGERY
GUIDELINE FOR THROMBOPROPHYLAXIS IN ADULT (18 YEARS AND OLDER) IN GENERAL MEDICAL PATIENTS AND INPATIENTS UNDERGOING SURGERY SEE SEPARATE GUIDELINES FOR THROMBOPROPHYLAXIS IN OBSTETRICS This guidance does
More informationConsensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture
Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture Patients with hip fractures should be operated on within 36 hours of presentation wherever possible.
More informationPrevention of Venous Thromboembolism
Prevention of Venous Thromboembolism Reference No: P_CS_05 Version 2.4 Ratified by: LCHS Trust Board Date ratified: 27 th January 2015 Name of originator / author: Medical Director Name of responsible
More informationTHROMBOPROPHYLAXIS POLICY FOR ADULT PATIENTS ADMITTED AS INPATIENTS. 362 Version No: 2 Previous Trust / LHB Ref No:
Reference No: THROMBOPROPHYLAXIS POLICY FOR ADULT PATIENTS ADMITTED AS INPATIENTS 362 Version No: 2 Previous Trust / LHB Ref No: 362 Documents to read alongside this Policy, Procedure etc (delete as necessary)
More informationPrevention and management of venous thromboembolism M. AAPRO
Prevention and management of venous thromboembolism M. AAPRO Thromboprophylaxisof DVT and PE in AmbulatoryCancerPatients Zurich, February 2017 M. AAPRO Based on a lesson in April 2016 by M. DICATO M.D.,
More informationHospital Acquired VTE: update on national guidance
Hospital Acquired VTE: update on national guidance Rebecca Chanda Consultant Pharmacist - Thrombosis and Haemostasis Guy s and St Thomas Hospitals NHS Foundation Trust Chair of the UK Clinical Pharmacy
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationNational Quality Improvement Project 2018/2019 VTE Risk in Lower Limb Immobilisation Information Pack
National Quality Improvement Project 2018/2019 VTE Risk in Lower Limb Immobilisation Information Pack Introduction... 2 Methodology... 3 Flow of data searches to identify audit cases... 3 Data entry information...
More informationconvey the clinical quality measure's title, number, owner/developer and contact
CMS-0033-P 153 convey the clinical quality measure's title, number, owner/developer and contact information, and a link to existing electronic specifications where applicable. TABLE 20: Proposed Clinical
More informationPage: 1 of 13. Post-Surgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Last Review Status/Date: March 2014 Page: 1 of 13 Compression Devices for Venous Description Patients undergoing major orthopedic surgery are at increased risk for venous thromboembolism (VTE). Patients
More informationMedicines Management Group
Title SHARED CARE PROTOCOL for Extended Treatment of symptomatic VTE and prevention of its recurrence in Cancer Patients with Solid and Haematological Tumours Scope: Dalteparin (Fragmin ) may be considered
More informationPreventing Blood Clots in Adult Patients
Manchester Royal Eye Hospital Surgical Services Information for Patients Preventing Blood Clots in Adult Patients This leaflet will give you information on how to reduce the risk of developing blood clots
More information